Progenics Pharmaceuticals, Inc.
http://www.progenics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Progenics Pharmaceuticals, Inc.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence
The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.
Kymera Puts Emphasis On Immunology In New Growth Phase
CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.
Otsuka Counts The Cost Of Alzheimer’s Agitation Fail
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
- Other Names / Subsidiaries
-
- Molecular Insight Pharmaceuticals, Inc.
- PSMA Development Company
- UR Labs (URL)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice